Skip to main content

Table 1 Characteristics of the included RCTs

From: Postoperative chemoradiotherapy versus chemotherapy for R0 resected gastric cancer with D2 lymph node dissection: an up-to-date meta-analysis

References Kwon et al. [14] Kim et al. [15] Zhu et al. [16] ARTIST 2012/2015
Characteristics CRT CT CRT CT CRT CT CRT CT
Patient number 31 30 46 44 186 165 230 228
Age year 56 (23–73) 49 (29–70) >60, (19.6 %) >60, (31.8 %) 56 (38–73) 59 (42–75) 56 (28–76) 56 (22–77)
Sex no. (%)
 Male 21 (67.7) 23 (76.7) 34 (73.9) 25 (56.8) 135 (72.9) 126 (76.4) 143 (62.2) 153 (67.1)
 Female 10 (32.3) 7 (23.3) 12 (26.1) 19 (43.2) 51 (27.1) 39 (23.6) 87 (37.8) 75 (32.9)
ECOG PS no. (%)         
 0 NR NR 35 (76.1) 27 (61.4) NR NR 99 (43.0) 96 (42.1)
 1 NR NR 11 (23.9) 17 (38.6) NR NR 131 (57.0) 132 (57.9)
Primary tumor site no. (%)
 Proximal 6 (16.1) 4 (13.3) 3 (6.5) 2 (4.5) 30 (16.1) 15 (9.1) 13 (5.7) 9 (3.9)
 Body 9 (29.0) 11 (36.7) 26 (56.5) 19 (43.2) 21 (11.3) 33 (20) 107 (46.5) 112 (49.1)
 Antrum 17 (54.8) 15 (50.0) 14 (30.5) 18 (40.9) 135 (72.6) 117 (70.9) 90 (39.1) 87 (38.2)
 Multiple/diffuse 0 0 3 (6.5) 5 (11.4) 0 0 20 (8.7) 20 (8.8)
Laurén’s classification no. (%)
 Intestinal 5 (16.1) 12 (40.0) 16 (34.8) 15 (34.1) NR NR 75 (32.6) 88 (38.6)
 Diffuse 20 (64.4) 13 (43.3) 26 (56.5) 24 (54.5) NR NR 144 (62.6) 130 (57.0)
 Mixed/unclassified 6 (19.4) 5 (16.7) 4 (8.6) 5 (11.3) NR NR 11 (4.8) 10 (4.4)
Tumor stage no. (%)
 Ib 0 0 0 0 20 (10.8) 15 (9.1) 49 (21.3) 50 (21.9)
 II 0 0 0 0 36 (19.4) 30 (18.2) 84 (36.5) 86 (37.7)
 III 24 (77.4) 27 (90.0) 34 (73.9) 31 (75.0) 103 (55.4) 96 (58.2) 71 (30.8) 65 (28.6)
 IV (M0) 7 (22.6) 3 (10) 12 (26.1) 11 (25.0) 27 (14.5) 24 (14.5) 26 (11.3) 27 (11.8)
 pN+ NR NR 46 (100) 42 (95.5) 158 (84.9) 143 (86.7) 203 (88.2) 193 (84.6)
Lymphadenectomy D2 D2 D2 D2
Treatment regimens FP/RT FP FL/RT FL FL/IMRT FL XP/XRT/XP XP
Total RT dose/technique 45 Gy/3D-CRT 45 Gy/AP-PA fields 45 Gy/IMRT 45 Gy/AP-PA fields
Endpoints 3-ys DFS: 80.0 % vs 75.2 %; P = 0.887
5-ys DFS: 76.7 % vs 59.1 %; P = 0.222
5-ys OS: 70.1 % vs 70.0 %; P = 0.814
5-ys DFS: 60.9 % vs 50.0 %; P = 0.246
5-ys OS: 65.2 % vs 54.6 %; P = 0.67
5-ys RFS: 45.2 % vs 35.8 %, P = 0.029
5-ys OS: 48.4 % vs 41.8 %, P = 0.122
3-ys DFS: 78.2 % vs 74.2 %; P = 0.0862
7-ys DFS: P = 0.740
5-ys OS: 75 % vs 73 %; P = 0.484
Median follow-up months 77.2 (24–92.8) 86.7 (60.3–116.5) 42.5 2012: 53.2(36.9–77.3)
2015: 7 years
  1. FP regimen: 5-Fu 1000 mg/m2 continuous infusion on days 1–5, cisplatin 60 mg/m2 on day 1 every 3 weeks, totally 6 cycles; FP/RT: 1 cycle of FP, then RT (45 Gy of radiation at 1.8 Gy per day, 5 days per week, for 5 weeks with continuous capecitabine 825 mg/m2 twice daily during radiotherapy), followed by 3 cycles of FP; FL regimen: 5-Fu 425 mg/m2, leucovorin 20 mg/m2, for 5 days with a 4-week interval, totally 5 cycles; FL/RT: 1 cycle of FL, then RT (45 Gy of radiation at 1.8 Gy per day, 5 days per week, for 5 weeks with 2 cycles of FL), followed by 2 cycles of FL; XP regimen: capecitabine 1000 mg/m2 twice daily on days 1 to 14; cisplatin 60 mg/m2 on day 1 every 3 weeks, totally 6 cycles; XP/XRT/XP: 2 cycles of XP, then XRT (45 Gy of radiation at 1.8 Gy per day, 5 days per week, for 5 weeks with continuous capecitabine 825 mg/m2 twice daily during radiotherapy), followed by 2 cycles of XP
  2. CT chemotherapy, CRT chemoradiotherapy, NR not reported, 3-ys DFS 3-year disease-free survival, 5-ys DFS 5-year disease-free survival, 5-ys OS 5-year overall survival, 3D-CRT 3D conformal radiotherapy, IMRT intensity-modulated radiotherapy, LN lymph node